XORTX Therapeutics Inc XRTX.V is expected to report results on May 19 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for XORTX Therapeutics Inc is for a loss of 33 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
This summary was machine generated May 16 at 20:47 GMT. All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)